Intensity Therapeutics, Inc. (INTS) Stock Analysis

Intensity Therapeutics, Inc. (INTS) Healthcare & Pipeline Overview

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel cancer therapies targeting solid tumors. Their lead candidate, INT230-6, is undergoing Phase 2 clinical trials and is being evaluated in combination with established therapies through collaborations with major pharmaceutical companies, positioning them in a competitive oncology market.

What Is the Investment Thesis for INTS?

Intensity Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily tied to the clinical success of INT230-6, currently in Phase 2 trials. Positive data from these trials, expected to be released incrementally over the next 12-24 months, could serve as a significant catalyst, potentially leading to increased investor interest and partnership opportunities. The collaborations with Merck and Bristol-Myers Squibb provide validation of the INT230-6 platform and offer potential revenue streams through milestone payments and royalties. However, the company's limited financial resources and reliance on clinical trial outcomes pose substantial risks. Failure to demonstrate efficacy or safety in ongoing trials would severely impact the company's valuation. The company's market capitalization of $10.9M reflects the speculative nature of this investment.

Based on FMP financials and quantitative analysis

INTS Key Highlights

INT230-6 is in Phase 2 clinical trials targeting a range of refractory solid tumors, indicating progress in clinical development.

• Collaboration agreements with Merck and Bristol-Myers Squibb validate the potential of INT230-6 and provide access to established therapies like Keytruda and Yervoy.
• Focus on intratumoral injection of INT230-6 represents a novel approach to cancer treatment, potentially offering advantages over systemic therapies.
• Partnership with Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research supports further research and development of INT230-6 in breast cancer.
• The company's small size (5 employees) allows for focused research efforts but also presents operational risks.

Who Are INTS's Competitors?

INTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are INTS's Key Strengths?

Novel intratumoral drug delivery technology.

• Collaboration agreements with major pharmaceutical companies.
• Phase 2 clinical trials underway for INT230-6.
• Focus on difficult-to-treat solid tumors.

What Are INTS's Weaknesses?

Limited financial resources.

• Small team size.
• Reliance on clinical trial success.
• High risk of clinical trial failure.

What Could Drive INTS Stock Higher?

INTS catalyst: Data readouts from ongoing Phase 2 clinical trials of INT230-6 in various solid tumors (next 6-18 months).

• Potential initiation of new clinical trials for INT230-6 in additional cancer types (next 12-24 months).
• Progress in collaboration agreements with Merck and Bristol-Myers Squibb.
• Advancements in research and development of next-generation intratumoral therapies.

What Are the Key Risks for INTS?

Financial-distress signal — its Altman Z-Score of -9.61 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for INT230-6.
• Regulatory delays or rejection of INT230-6.
• Competition from other cancer drug developers.
• Limited financial resources and reliance on external funding.
• Patent expiration and loss of exclusivity for INT230-6.

What Are the Growth Opportunities for INTS?

• Expansion of INT230-6 Clinical Trials: Intensity Therapeutics has the opportunity to expand the clinical trials for INT230-6 to include additional cancer types and patient populations. This would broaden the potential market for the drug and increase its commercial value. The market for cancer therapeutics is projected to reach $250 billion by 2028, providing a significant opportunity for growth. Timeline: Ongoing, with new trials potentially initiated in the next 12-24 months.
• Securing Additional Partnerships: The company can pursue additional partnerships with pharmaceutical companies to further develop and commercialize INT230-6. These partnerships could provide additional funding, resources, and expertise. The pharmaceutical industry is actively seeking innovative cancer therapies, creating a favorable environment for partnerships. Timeline: Ongoing, with potential for new partnerships in the next 12-36 months.
• Development of Next-Generation Intratumoral Therapies: Intensity Therapeutics can leverage its expertise in intratumoral drug delivery to develop next-generation therapies with improved efficacy and safety profiles. This would strengthen its competitive position and create new revenue streams. The market for targeted drug delivery systems is growing rapidly, driven by the need for more effective and less toxic cancer treatments. Timeline: Long-term, with research and development efforts ongoing.
• Out-licensing or Acquisition: The company could out-license or be acquired by a larger pharmaceutical company. This would provide a significant return on investment for shareholders. The pharmaceutical industry is actively consolidating, with larger companies acquiring smaller biotech firms with promising drug candidates. Timeline: Uncertain, but potential for an acquisition in the next 3-5 years.
• Positive Clinical Trial Data Readouts: Upcoming data readouts from ongoing Phase 2 clinical trials represent a significant growth opportunity. Positive results could lead to increased investor confidence, higher stock valuation, and accelerated development timelines. The success of INT230-6 hinges on demonstrating efficacy and safety in these trials. Timeline: Near-term, with data readouts expected in the next 6-18 months.

What Are INTS's Competitive Advantages?

• Proprietary INT230-6 formulation and intratumoral delivery technology.
• Established collaborations with major pharmaceutical companies like Merck and Bristol-Myers Squibb.
• Patent protection for INT230-6 and related technologies.
• Expertise in intratumoral drug delivery and cancer biology.

What Does INTS Do?

Intensity Therapeutics, Inc., founded in 2012 and headquartered in Westport, Connecticut, is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative cancer drugs for the treatment of solid tumors. The company's primary focus is on its lead product candidate, INT230-6, a novel drug designed for direct intratumoral injection. INT230-6 is currently in Phase 2 clinical trials, targeting a range of refractory solid tumors, including pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. This therapeutic approach aims to induce tumor cell death and stimulate an anti-tumor immune response. Intensity Therapeutics has established strategic collaboration agreements with Merck Sharpe & Dohme Corp. to evaluate INT230-6 in combination with Keytruda, focusing on advanced pancreatic, colon, squamous cell, and bile duct malignancies. Additionally, they are collaborating with Bristol-Myers Squibb Company to assess the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers. Further research is being conducted in partnership with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company's business model centers on advancing INT230-6 through clinical trials and securing partnerships to broaden its therapeutic applications and market reach.

What Products and Services Does INTS Offer?

• Develop cancer drugs to treat solid tumors.
• Focus on intratumoral injection as a method of drug delivery.
• Conduct Phase 2 clinical trials for INT230-6.
• Collaborate with pharmaceutical companies to evaluate INT230-6 in combination with other therapies.
• Partner with research institutions to study INT230-6 in various cancer types.
• Engage in the discovery of new cancer drug candidates.

How Does INTS Make Money?

• Develop and patent novel cancer therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through milestone payments, royalties, and potential future product sales.

What Industry Does INTS Operate In?

Intensity Therapeutics operates within the highly competitive biotechnology industry, specifically focusing on oncology. The market for cancer therapeutics is substantial and growing, driven by an aging population and advancements in cancer research. The company's approach of direct intratumoral injection of INT230-6 differentiates it from companies developing systemic therapies. Key trends in the industry include the rise of immunotherapy, personalized medicine, and combination therapies. Intensity Therapeutics' collaborations with Merck and Bristol-Myers Squibb align with the trend of combining novel agents with established immunotherapies to enhance efficacy. The competitive landscape includes major pharmaceutical companies and numerous smaller biotech firms developing cancer drugs.

Who Are INTS's Key Customers?

• Pharmaceutical companies seeking to expand their oncology portfolios.
• Cancer patients with refractory solid tumors who may benefit from INT230-6.
• Research institutions interested in collaborating on cancer research projects.

Company Profile

Intensity Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Shelton, US. The company is led by CEO Lewis H. Bender. INTS has traded publicly since 2023.

Intensity Therapeutics, Inc. Financial Trajectory

Intensity Therapeutics, Inc. (INTS) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $3.0M, with diluted EPS of $-0.11. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, INTS averaged $-0.50 in diluted EPS.

How Intensity Therapeutics, Inc. Is Valued

Intensity Therapeutics, Inc. carries a market capitalization of $10.9M, placing it in the micro-cap category. Analyst price targets span from $7.00 to $15.00, with a consensus of $11.00. At the current price of $4.04, that implies approximately 172% upside potential.

Key Financial Metrics

Return on assets is -87.0%, showing how much profit it generates from its asset base. A current ratio of 4.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.3%, the inverse of the P/E and a quick read on earnings relative to price.

Intensity Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.61 places it in the distress zone, a signal of elevated financial risk.

Intensity Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 127.9% below estimates on average.

Over the past six months, Intensity Therapeutics, Inc. insiders filed 10 SEC Form 4 transactions — 0 sales and 10 purchases. On net that is roughly 188K shares acquired (about $958K) — insiders putting money in tends to read as conviction.

INTS Financials

INTS Latest News

INTS Analyst Consensus

INTS MoonshotScore

INTS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources